Scientific Committee

Joseph F Goldberg, MD

Clinical Professor of Psychiatry
Icahn School of Medicine
Mount Sinai
New York, New York

" We are increasingly learning how best to subclassify patients with bipolar depression, which in turn helps us choose from among a growing array of effective, evidence-based treatments in order to minimize treatment resistance and optimize outcomes. "

John M Kane, MD

Chairman of Psychiatry
Hofstra Northwell School of Medicine
Manhasset, New York

Relapse in patients with schizophrenia can interfere with recovery, and we should do everything that we can to prevent it. ”

Roger S. McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
University of Toronto
Toronto, Ontario, Canada

" We are now able to identify diagnostic subtypes that are clinically relevant to mood disorders and treatment. "

Alan F. Schatzberg, MD

Kenneth T. Norris, Jr., Professor
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine

" Psychedelics for treating major depression and anxiety combines powerful pharmacology with a psychosocial intervention and offers an opportunity for developing novel combination treatment strategies. "

Manpreet K. Singh, MD, MS

Associate Professor and Akiko Yamazaki and Jerry Yang Faculty
Scholar in Pediatric Translational Medicine
Department of Psychiatry and Behavioral Sciences
Director, Pediatric Mood Disorders Program
Director, Pediatric Emotion and Resilience Lab
Stanford University School of Medicine